virologic response rate
Recently Published Documents


TOTAL DOCUMENTS

19
(FIVE YEARS 0)

H-INDEX

5
(FIVE YEARS 0)

2017 ◽  
Vol 12 (1) ◽  
pp. 12 ◽  
Author(s):  
Hussien Ahmed ◽  
Abdelrahman Ibrahim Abushouk ◽  
Mohamed Gadelkarim ◽  
Arwa Mohamed ◽  
Mohamed Gabr ◽  
...  

<p class="Abstract">Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes. Therefore, we conducted this systematic review to investigate the efficacy of daclatasvir in HCV genotype 4 treatment. A computer literature search of PubMed, Scopus, Embase, Ovid, Web of knowledge, and Cochrane central was conducted. We selected studies comparing daclatasvir plus peginterferon-alfa/ribavirin versus placebo plus peginterferon-alfa/ribavirin in patients with HCV genotype 4 infection.  Pooling data from two randomized controlled trials (n = 154 patients) showed that daclatasvir/peg-interferon/ribavirin treatment achieved a moderate sustained virologic response rate of 76% after 12 weeks and of 79% after 24 weeks. The daclatasvir containing regimen was superior to the placebo containing regimen in terms of virologic response rates after 12 weeks (RR=1.9% CI 1.3 to 2.6) and 24 weeks (RR=1.8% CI 1.3 to 2.5). More effective regimens are needed for HCV genotype 4.</p>


2016 ◽  
Vol 4 (2) ◽  
Author(s):  
Hasan Vosoghinia ◽  
Abbas Esmaeilzadeh ◽  
Azita Ganji ◽  
Seyed Mousal-Reza Hosseini ◽  
Saeid Amel Jamehdar ◽  
...  

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A3.2-A3
Author(s):  
R López-Sepúlveda ◽  
C García-Collado ◽  
J Pérez-Morales ◽  
CM Valencia Soto ◽  
FJ Orantes ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document